$STOCK UNDERGROUND$

[Investor100]

DARA @ Stockcharts

Stock blasting out the doors in 2014 with much anticipation...MFI turning back up and the 200MA around the corner...some nice designations "Fast Track Drug and and seeking "Orphan Status" all good news...watching closely for a position.

http://finance.yahoo.com/news/dara-biosciences-completes-breast-cancer-133000249.html
DARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.

In 2014, DARA kicks off its new partnership with Alamo Pharma Services, a subsidiary of Mission Pharmacal, in deploying a dedicated 20-person national sales team in the U.S. oncology market. In addition to promoting DARA's products Soltamox® (tamoxifen citrate), Gelclair® and Bionect®, this specialized oncology supportive care sales team also will provide clinicians with access to three Mission Pharmacal products: Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral® (for chemotherapy/radiation therapy-induced dry mouth).

DARA: Building An Oncology And Supportive Care Specialty Pharma
http://finance.yahoo.com/news/dara-building-oncology-supportive-care-120000065.html